Melatonin Attenuates Early Brain Injury Via Regulating Mir-181a/Tnf-A/Nf-Kb Signaling Pathway Following Subarachnoid Hemorrhage In Rat

Yi Wang,Yongbo Yang,Shijie Na,Tao Liu,Chunhua Hang,Binghua Jiang,Yongpin You
DOI: https://doi.org/10.19193/0393-6384_2020_6_533
2020-01-01
Acta medica mediterranea
Abstract:Increasing studies have demonstrated that melatonin is a beneficial supplement in the treatment of central nervous system (CNS) disorders. However, limited studies have evaluated the regulatory effect of melatonin (Mel) on subarachnoid haemorrhage (SAH). The purpose of this study was to explore the potential role of melatonin in early brain injury (EBI) induced by SAH and to investigate the underlying mechanisms. The expression profile of miRNAs was examined in SAH+Mel samples and compared with SAH samples with microarray analysis. A set of differentially expressed miRNAs was identified, including miR-181a. Through bioinformatics analysis, TNF-alpha was predicted to be a target gene. Adult rats were subjected to SAH. Melatonin or vehicle was injected intraperitoneally 2 hr after SAH. Mortality, neurological score, brain water content, SAH grade, and neuronal apoptosis were evaluated. Ti) explore the mechanisms further, the change in the TNF-alpha/NF-kappa B signalling pathway and the levels of apoptosis associated proteins were also examined. Our results indicated that melatonin improved the neurological deficits and reduced the brain water content and neuronal apoptosis. In addition, the iniR-181a mimic and inhibitor were applied to manipulate the TNF-alpha/NF-kappa B pathway. Mortality, neurological scores, brain oedema, cell apoptosis, and expression of TNF-alpha, p6.5 and I kappa B alpha proteins were assayed after 24 h SAH. Melatonin significantly improved neurological function and reduced both neuronal apoptosis and brain oedema at 24 h after SAH. The expression level of TNF-alpha and p65 were markedly downregulated. Additionally, the level of caspase-3 was decreased while bcl-2 was increased with melatonin treatment. In addition, miR-181a synergistically improved neurological function. In summary, our results demonstrate that melatonin attenuates the EBI following SAH via miR-181a1 TNF-alpha/NF-kappa B signalling. miR-181a targeted-inhibition of TNF-alpha presents a promising therapeutic strategy for the treatment of SAH.
What problem does this paper attempt to address?